Regulus Therapeutics Inc (RGLS) was Reiterated by Chardan Capital Markets to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 20 from a previous price target of $15 . Chardan Capital Markets advised their investors in a research report released on Jun 7, 2016.
Many Wall Street Analysts have commented on Regulus Therapeutics Inc. Chardan Capital Markets Initiated Regulus Therapeutics Inc on Apr 13, 2016 to “Buy”, Price Target of the shares are set at $15.
Regulus Therapeutics Inc closed down -0.37 points or -5.97% at $5.83 with 7,12,518 shares getting traded on Friday. Post opening the session at $6.21, the shares hit an intraday low of $5.78 and an intraday high of $6.23 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Mar 7, 2016, Joseph P Hagan (COO) purchased 10,000 shares at $7.19 per share price. According to the SEC, on Aug 13, 2015, Mark G Foletta (director) purchased 10,000 shares at $7.64 per share price. On Jul 21, 2015, William H Rastetter (director) purchased 100,000 shares at $10.16 per share price, according to the Form-4 filing with the securities and exchange commission.
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Companys Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease which is designed to support its therapeutic pipeline collaborators and strategic partners. Its development programs include microRNA target miR-122 miR-21 RG-012 miR-103/107 miR-19 miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.